康恩贝：康恩贝集团拟向控股股东转让2%公司股份

Core Viewpoint - Kang En Bei (600572) announced on December 22 that its second-largest shareholder, Kang En Bei Group, plans to reduce its stake in the company by up to 50.659 million shares, representing a maximum reduction of 2% of the company's total share capital [1] Group 1 - The reduction will be executed through a block trade [1] - The controlling shareholder, Zhejiang Pharmaceutical Group, will be the buyer of the shares being sold by Kang En Bei Group [1]